Now, a new Phase 1 trial led by researchers at Children’s National Hospital showed that a new autologous multi-antigen T cell therapy can be delivered intravenously and reach the brain through the bloodstream to fight off brain tumors in children. Read more: https://www.drugdiscoverynews.com/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-17325

Researchers from Fox Chase Cancer Center have identified a widely used thyroid hormone that may significantly improve treatment outcomes for medulloblastoma, the most common malignant brain tumor in children. Read more: https://medicalxpress.com/news/2026-07-common-thyroid-hormone-brain-tumor.html

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors. Read more: https://medicalxpress.com/news/2026-06-tcell-therapy-tumor-proteins-early.html

Through advanced genetic sequencing, chemotherapy and the expertise of a large medical team, doctors were able to identify a treatment approach tailored to Hadley's unique tumor. With the help of precision medicine and months of treatment, Hadley began defying expectations. Read more: https://www.cbsnews.com/colorado/news/childhood-brain-stem-cancer-survivor-colorado-girl/

A Children’s Hospital Los Angeles study has shed new light on the molecular drivers of FOXR2-activated CNS neuroblastoma, an extremely rare pediatric brain tumor that can be difficult to diagnose without advanced testing. Read more: https://www.newswise.com/articles/children-s-hospital-los-angeles-researchers-uncover-genetic-clues-to-rare-childhood-brain-tumor

Physical functioning is significantly diminished by intensive management of childhood posterior fossa brain tumors (PFTs) and correlates with survivors’ neurologic treatment burdens, suggests research presented at the 51st Annual ONS Congress in San Antonio, Texas. Read more: https://www.oncologynurseadvisor.com/reports/brain-tumors-functional-challenges-long-term-pediatric-pft/

In a study published in Cell Death & Disease, researchers led by Blanco identified a potential way to reduce relapse in medulloblastoma by targeting the tumor cells most likely to survive treatment and drive regrowth. Read more: https://www.news-medical.net/news/20260526/Scientists-target-root-of-relapse-in-aggressive-childhood-brain-tumors.aspx

For pediatric brain tumor survivors (PBTS), the necessity and challenge of sustaining meaningful friendships is more pronounced due to differences in social, emotional and neurocognitive abilities, areas collectively called psychosocial functioning. Read more: https://www.stjude.org/research/progress/2026/understanding-best-friendships-and-psychosocial-health-in-pediatric-brain-tumor-survivors.html

Blocking energy production pathways in an aggressive type of brain cancer in children could be a promising new therapeutic strategy, according to research in mice by Johns Hopkins Kimmel Cancer Center investigators. Read more: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2026/04/blocking-energy-metabolism-may-help-treat-aggressive-pediatric-brain-tumor

Diagnosed with DIPG at age six, Lucas’ doctor Jacques Grill told Lucas’ parents, Cedric and Olesja, that he was unlikely to live very long. Instead of giving up hope, Cedric and Olesja flew Lucas to France to participate in a clinical trial called BIOMEDE, which tested new potential drugs against DIPG. Read more: https://www.upworthy.com/first-person-cured-of-dipg-ex1/